Delacretaz A, Lagares Santos P, Saigi Morgui N, Vandenberghe F, Glatard A, Gholam-Rezaee M, von Gunten A, Conus P, Eap CB. Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs. Pharmacogenet Genomics. 2017 Dec 1;27(12):464-72. doi: 10.1097/FPC.0000000000000313
Vandenberghe F, Saigi-Morgui N, Delacretaz A, Quteineh L, Crettol S, Ansermot N, Gholam-Rezaee M, von Gunten A, Conus P, Eap CB. Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers. Pharmacogenet Genomics. 2016 Dec;26(12):547-57. doi: 10.1097/FPC.0000000000000249
Saigi-Morgui N, Vandenberghe F, Delacretaz A, Quteineh L, Gholamrezaee M, Aubry JM, von Gunten A, Kutalik Z, Conus P, Eap CB. Association of genetic risk scores with body mass index in Swiss psychiatric cohorts. Pharmacogenet Genomics. 2016 May;26(5):208-17. doi: 10.1097/FPC.0000000000000210
Quteineh L, Vandenberghe F, Saigi Morgui N, Delacretaz A, Choong E, Gholam-Rezaee M, Magistretti P, Bondolfi G, von Gunten A, Preisig M, Castelao E, Vollenweider P, Waeber G, Bochud M, Kutalik Z, Conus P, Eap CB. Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments. Pharmacogenet Genomics. 2015 May;25(5):246-58. doi: 10.1097/FPC.0000000000000131
Cobos A, Sánchez P, Aguado J, Carrasco JL. Methodological quality in pharmacogenetic studies with binary assessment of treatment response: a review. Pharmacogenet Genomics. 2011 May;21(5):243-50.
Yen L, Davis K, Longstreth G, Streck P, Hodgkins P. Resource utilization and health care costs associated with diverticulitis: results from a retrospective claims database analysis. Am J Gastroenterol. 2010 Oct 1;105(Suppl. 1):S431.
Carson R, Williams V, Nelson L, MacDougall J, Johnston J. Psychometric evaluation of patient-reported outcome measures for assessing IBS-c symptom severity and global change: results from a phase 2b study of linaclotide. Am J Gastroenterol. 2009 Oct 1;104:1113.
Mangel AW, Fehnel SE. Adequate relief in IBS treatment trials: corrections to errors stated by Whitehead et al. Am J Gastroenterol. 2006 Dec;101(12):2884-5.
Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2004;99:1-9.
Northcutt AR, Perschy TL, Ameen VZ, Hamedani AG, McSorley DJ, Carter EG. Most bothersome symptoms in irritable bowel syndrome (IBS) patients. Am J Gastroenterol. 2004;99(10):842.
Northcutt AR, Perschy TL, Ameen VZ, Hamedani AG, McSorley DJ, Carter EG. Correlating global outcome measures in Irritable Bowel Syndrome (IBS). Am J Gastroenterol. 2004;99(10):843.
Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol. 2001 Mar;96(3):803-11.
Schwartz HI, Perschy TB, McSorley DJ, Sorrells SC. Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. Am J Gastroenterol. 1999 Jun;4(2):121-7.
Mangel AW, Northcutt AR, Kong S, McSorley DJ. Validation of adequate relief as an endpoint in irritable bowel syndrome. Am J Gastroenterol. 1999;116:G4500.
Calvet X, Navarro M, Gil M, Lafont A, Sanfeliu I, Brullet E, Campo R, Dalmau B, Rivero E, Mas P. Epidemiology of peptic ulcer disease in cirrhotic patients: role of helicobacter pylori infection. Am J Gastroenterol. 1998 Dec;93(12):2501-7.
Vakil N, McSorley DJ, Hahn BA. Clarithromycin-resistant helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol. 1998 Sep;93(9):1432-5.
Ciociola AA, McSorley DJ. Consistent criteria should be employed in calculating h. pylori (HP) eradication rates: application of different published study criteria to ranitidine bismuth citrate (RBC) clinical trial data. Am J Gastroenterol. 1996;91(9):1907.
Graham DY, Hirshowitz B, Ciociola AA, Sykes DL, McSorley DJ. Ranitidine bismuth citrate plus amoxicillin for the treatment of duodenal ulcer disease. Am J Gastroenterol. 1995;90(9):638.
Johnson JA, Euler AR, Northcutt AR, McSorley DJ. Ranitidine 300mg at bedtime is effective for gastric ulcers: a 12-week, multicenter, randomized, double-blind, placebo-controlled comparison. Am J Gastroenterol. 1993;88(7):1071-5.
Marshall B, Ciociola AA, McSorley DJ, Webb DD. Computerized phone-in symptom recording system correlates with patient recorded symptom diary card for patients with non-ulcer dyspepsia. Am J Gastroenterol. 1993;91(9):1992.
Euler AR, Johnson JA, Dawson D, Kleoudis C, McSorley DJ. A comparison of ranitidine 150mg and placebo administered at bedtime for maintenance of recurrent benign gastric ulcers. Am J Gastroenterol. 1992;87(9):1267.